Management of endothelial disease without keratoplasty

Curr Opin Ophthalmol. 2022 Jul 1;33(4):332-337. doi: 10.1097/ICU.0000000000000854.

Abstract

Purpose of review: Currently, the most widely used treatment for endothelial disease is endothelial replacement via endothelial keratoplasty. Increasingly selective techniques have allowed for increased safety and faster visual recovery. However, alternative treatment options that are lower in cost, require less surgical expertise, and rely less on tissue availability are needed. This review discusses established and emerging therapies for endothelial disease without keratoplasty.

Recent findings: Regenerative therapies that have been successful include Descemet stripping only and Descemet membrane transplants. Rho-kinase inhibitors promote cell proliferation, adhesion, and migration and appear to have a role in these treatments and possibly in the prevention of endothelial disease. Cell-based therapies and the development of an artificial endothelial implant have also demonstrated promising results.

Summary: There are numerous emerging treatments for endothelial disease that have proven successful. Advances in our understanding of disease pathogenesis on a cellular level will continue to expand possibilities for therapeutics.

Publication types

  • Review

MeSH terms

  • Cell Proliferation
  • Cell- and Tissue-Based Therapy
  • Corneal Diseases* / pathology
  • Corneal Diseases* / surgery
  • Descemet Stripping Endothelial Keratoplasty* / methods
  • Endothelium, Corneal / pathology
  • Humans